These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17786198)

  • 1. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.
    Miranda A; Morgan M; Jamal L; Laserson K; Barreira D; Silva G; Santos J; Wells C; Paine P; Garrett D
    PLoS One; 2007 Sep; 2(9):e826. PubMed ID: 17786198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of highly active antiretroviral treatment with incident tuberculosis in people living with HIV/AIDS.
    Yen YF; Jen IA; Chuang PH; Chen M; Lan YC; Lee CY; Arthur Chen YM
    Ann Epidemiol; 2018 Dec; 28(12):886-892.e3. PubMed ID: 29656849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
    Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India.
    Dravid A; Natarajan K; Medisetty M; Gawali R; Mahajan U; Kulkarni M; Saraf C; Ghanekar C; Kore S; Rathod N; Dravid M
    BMC Infect Dis; 2019 Aug; 19(1):714. PubMed ID: 31409289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso.
    Dembélé M; Saleri N; Carvalho AC; Saouadogo T; Hien AD; Zabsonre I; Koala ST; Simporé J; Matteelli A
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):318-23. PubMed ID: 20132623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.
    Schmaltz CA; Santoro-Lopes G; Lourenço MC; Morgado MG; Velasque Lde S; Rolla VC
    PLoS One; 2012; 7(9):e45704. PubMed ID: 23049842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort.
    Martinson NA; Moultrie H; van Niekerk R; Barry G; Coovadia A; Cotton M; Violari A; Gray GE; Chaisson RE; McIntyre JA; Meyers T
    Int J Tuberc Lung Dis; 2009 Jul; 13(7):862-7. PubMed ID: 19555536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil.
    dos Santos AP; Pacheco AG; Staviack A; Golub JE; Chaisson RE; Rolla VC; Kritski AL; Passos SR; de Queiroz Mello FC
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):192-7. PubMed ID: 23317954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy.
    Liu E; Makubi A; Drain P; Spiegelman D; Sando D; Li N; Chalamilla G; Sudfeld CR; Hertzmark E; Fawzi WW
    AIDS; 2015 Jul; 29(11):1391-9. PubMed ID: 26091295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008.
    Auld AF; Mbofana F; Shiraishi RW; Alfredo C; Sanchez M; Ellerbrock TV; Nelson LJ
    PLoS One; 2013; 8(1):e54665. PubMed ID: 23349948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.
    Hermans SM; Kiragga AN; Schaefer P; Kambugu A; Hoepelman AI; Manabe YC
    PLoS One; 2010 May; 5(5):e10527. PubMed ID: 20479873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
    Hung CC; Chen MY; Hsiao CF; Hsieh SM; Sheng WH; Chang SC
    AIDS; 2003 Dec; 17(18):2615-22. PubMed ID: 14685055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil.
    Saraceni V; Durovni B; Cavalcante SC; Cohn S; Pacheco AG; Moulton LH; Chaisson RE; Golub JE
    Braz J Infect Dis; 2014; 18(5):491-5. PubMed ID: 24780362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
    Golub JE; Pronyk P; Mohapi L; Thsabangu N; Moshabela M; Struthers H; Gray GE; McIntyre JA; Chaisson RE; Martinson NA
    AIDS; 2009 Mar; 23(5):631-6. PubMed ID: 19525621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.
    Martín-Echevarria E; Serrano-Villar S; Sainz T; Moreno A; Casado JL; Dronda F; Elías MJ; Navas E; Zapata MR; Moreno S
    Int J Tuberc Lung Dis; 2014 Sep; 18(9):1080-4. PubMed ID: 25189556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?
    Pettit AC; Jenkins CA; Stinnette SE; Rebeiro PF; Blackwell RB; Raffanti SP; Shepherd BE; Sterling TR
    J Acquir Immune Defic Syndr; 2011 Aug; 57(4):305-10. PubMed ID: 21423024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study.
    Assefa A; Gelaw B; Getnet G; Yitayew G
    BMC Infect Dis; 2014 Aug; 14():468. PubMed ID: 25164855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.
    Grinsztejn B; Veloso VG; Pilotto JH; Campos DP; Keruly JC; Moore RD
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):515-20. PubMed ID: 17558332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
    Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
    J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.